diagenics
supporting biomedical research

New! Lispro NL-ELISA

The Mercodia Lispro NL-ELISA for the quantitative determination of insulin lispro, with NO cross-reactivity to endogenous insulin or other insulin analogs.

Fully validated for use with human and porcine samples
No interference from insulin auto-antibodies
Broad measuring range – 1 – 500mU/L
No pre-treatment or dilution of samples
Low sample volume – 10ul
Results in 2h 15min
Enzyme immunoassay with chemiluminescent detection

Test Characteristics

The assay has been validated according to industry guidelines. Selected studies are presented here. Additional data can be obtained from Mercodia.

Sensitivity and Range of Quantification

Capability of Detection is 0.36 mU/L as determined by the methodology described in ISO11843-Part 4.

Lower Limit of Quantification, LLOQ, is 1.0 mU/L as determined according to EMA/FDA guidelines.

The Upper Limit of Quantification, ULOQ, is 500 mU/L as determined according to EMA/FDA guidelines.

Precision and Accuracy

Human EDTA plasma samples were spiked with EDQM Lispro and analyzed in 4 replicates on 6 occasions by 2 different technicians on 2 days. Precision and accuracy were calculated.

Samples

The Mercodia Lispro NL-ELISA can be used without any pre-treatment of samples. No dilution of samples is needed due to the broad measurement range of the assay.

The required sample volume is 10 µL.

Test Principle

Mercodia Lispro NL-ELISA is a solid phase two-site enzyme immunoassay based on the sandwich technique, in which two monoclonal antibodies are directed against separate antigenic determinants on the insulin lispro molecule. Lispro in the sample reacts with anti-lispro antibodies bound to microtitration wells and peroxidase-conjugated anti-lispro antibodies in the solution.